| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6855703 | ASPEN | Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
Feb, 2021
(3 years ago) | |
| US6660726 | ASPEN | Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same |
Mar, 2021
(3 years ago) | |
Enjuvia is owned by Aspen.
Enjuvia contains Estrogens, Conjugated Synthetic B.
Enjuvia has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Enjuvia are:
- US6855703
- US6660726
Enjuvia was authorised for market use on 20 December, 2004.
Enjuvia is available in tablet;oral dosage forms.
Enjuvia can be used as treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause, treatment of moderate to severe vasomotor symptoms associated with menopause.
The generics of Enjuvia are possible to be released after 08 March, 2021.
Drugs and Companies using ESTROGENS, CONJUGATED SYNTHETIC B ingredient
Market Authorisation Date: 20 December, 2004
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause; Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associa...
Dosage: TABLET;ORAL
ENJUVIA family patents
